Abstract. Chemotaxis allows polymorphonuclear neutrophils (PMN) to rapidly reach infected and inflamed sites. However, excessive influx of PMN damages host tissues. Better knowledge of the mechanisms that control PMN chemotaxis may lead to improved treatments of inflammatory diseases. Recent findings suggest that ATP and adenosine are involved in PMN chemotaxis. Therefore, these purinergic signaling processes may be suitable targets for novel therapeutic approaches to ameliorate host tissue damage.
Introduction
Up to 70 % of all leukocytes in the peripheral blood of healthy adults are polymorphonuclear neutrophils (PMN). PMN play an important role in the innate immune defense. They are well equipped to detect the presence of invading micro-organisms, to accurately locate such invaders at sites of infection, and to rapidly migrate to these sites where PMN kill the invaders by unleashing a powerful set of defensive tools that include reactive oxygen species (ROS), proteolytic enzymes, and bactericidal mediators stored in intracellular granules of PMN or deposited into the extracellular space in DNA-containing structures that have been termed NETs [1 -3] . PMN liberate these cytotoxic agents to incapacitate and destroy micro-organisms, but often host tissues are also compromised in the process. In fact, collateral damage to host tissues by excessively activated PMN is a hallmark of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma [4 -6] . During acute inflammatory episodes caused by shock, ischemia, and reperfusion, PMNinduced tissue damage is responsible for severe clinical complications such as acute lung injury (ALI) and acute respiratory distress syndrome (
ARDS) A C H T U N G T R E N N U N G A C H T U N G T R E N N U N G -A C H T U N G T R E N N U N G A C H T U N G T R E N N U N G A C H T U N G T R E N N U N G leading causes of death in trauma patients
suffering post-traumatic shock [7 -10] .
It is unclear what triggers this undiscriminating and overzealous response of PMN. Therapeutic approaches to treat these inflammatory diseases may target a wide range of processes that are involved in the initial activation of PMN or their recruitment to inflamed tissues; other approaches focus on the neutralization of cytotoxic mediators like elastase that are released from activated PMN. Among these potential therapeutic targets, PMN recruitment to inflamed tissues is the most promising. Indeed, a number of drugs have been developed to prevent the sequestration of PMN into affected host tissues [11 -15] . Of particular interest is PMN chemotaxis, as this is a key process involved in the recruitment of PMN to sites of inflammation. However, a more complete understanding of the mechanisms that control PMN chemotaxis is required to develop novel therapeutic strategies that effectively reduce chemotaxis and PMN-induced tissue damage.
Life cycle of PMN
PMN are formed by continuous differentiation of hematopoietic stem cells in the bone marrow through a process referred to as granulopoiesis. Myeloblasts differentiate into promyloblasts, myelocytes, and then metamyelocytes as well as segmented band neutrophils that can be found in circulation during stress [16 -19] . Metamyelocytes are the precursors of polymorphonuclear leukocytes, which are commonly referred to as granulocytes, including eosinophils, basophils, and neutrophils (PMN). The newly generated PMN are stored in the bone marrow, from where they can be rapidly released into the blood stream when needed. This process is tightly regulated, allowing significant increases in granulopoiesis and in the circulating PMN population to facilitate host defense, when PMN turnover can increase ten-fold and PMN counts in peripheral blood can surge to levels several fold higher than under normal conditions. Granulocyte colonystimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (G-CSF), interleukin (IL)-3, IL-23, and IL-17 are key mediators that regulate the production of PMN [20, 21] . In addition to these regulatory mediators, the mechanisms that control the migration of PMN within the bone marrow as well as their delivery to the bloodstream determine the final rate at which PMN are dispatched in response to inflammation or infection.
Extravasation
Upon their release from the bone marrow, PMN can circulate in the vasculature for several hours before they are finally recruited to inflamed tissues in order to pursue microbial invaders or to eliminate dead or dying cells. Numerous different chemokines and chemoattractant mediators that are produced by bacteria or by infected and inflamed tissues control the recruitment of PMN from the bloodstream into affected tissues. Adhesion molecules such as E-, L-, and P-selectins facilitate ever tighter interactions of circulating PMN with the endothelial cell layer lining the blood vessels closest to inflamed or infected host tissues [2, 11] . Initially, P-selectin is rapidly mobilized to the cell surface of the endothelial cell layer coating blood vessels of the microcirculation. Adhesion molecules on PMN such as P-selectin ligand-1 (PSGL-1) are concentrated on the tips of microvilli that protrude from circulating PMN, allowing the PMN to interact with P-selectin, which results in tethering of PMN to the endothelium. Together with the vasodilatation of capillaries in inflamed tissues, this process of tethering slows circulating PMN, resulting in the "rolling" of PMN along the endothelium of the microcirculation. In this microenvironment, PMN can become stimulated by mediators such as platelet-activating factor (PAF), leukotriene B 4 (LTB 4 ), and IL-8 that are generated by the inflamed endothelium [11, 22] . Upon binding of these mediators to receptors on the cell surface of PMN, the cells express b 2 -integrins (CD11/CD18 and LFA-1) stored in intracellular granules as well as a number of additional integrins such as a 4 b 1 -integrins [23 -25] . With the help of these integrins, PMN bind more tightly to the endothelium by recognition of endothelial adhesion molecules such as intercellular adhesion molecules (ICAMs) and vascular cell adhesion molecule-1 (VCAM-1) [23 -25] . These PMN-endothelial interactions culminate in the firm adherence and spreading of PMN on the endothelium, which allows PMN to penetrate the endothelial cell layer in order to transmigrate into the extravascular space. Extravasation of PMN into the extravascular space is known to occur in a paracellular manner at endothelial cell junctions where molecules such as platelet endothelial adhesion molecule-1 (PECAM-1), expressed at these regions of endothelial cell layers, appear to play important roles in facilitating transmigration [26] . In addition to this paracellular transmigration process, transcellular migration of PMN across the endothelial cell layer can also occur. In the latter case, PMN seem to penetrate and travel through individual endothelial cells at non-junctional locations without impairing endothelial cell integrity [24, 25] . Once in the extravascular space, PMN migrate upstream in chemotactic gradient fields generated by chemotactic mediators that are released at inflamed sites (Fig. 1) .
PMN chemotaxis
In contrast to random cell migration (chemokinesis), chemotaxis denotes the ability of cells to migrate in a directed fashion upstream in a chemotactic gradient field. This process requires coordinated and directional cytoskeletal rearrangements, mediated via Factin polymerization, that produce pseudopods at the leading edge in the direction of the chemotactic gradient field [27] . In order to produce appropriate pseudopods that result in chemotaxis rather than merely in random membrane ruffling or in cell spreading, F-actin polymerization is restricted to the leading edge, while extension of the leading edge is synchronized with myosin responses that induce the retraction of cell membrane at the receding edge (uropod). This is accomplished through contractile forces generated by myosin motor proteins and the consequent interactions with actin filaments at lateral and posterior regions of the cell cortex [27 -29] . Chemotaxis requires at least three distinct processes that accomplish gradient sensing, polarization within the gradient field, and migration itself (locomotion). Gradient sensing is necessary to detect the orientation of the chemotactic gradient field. PMN accomplish this task by recognizing chemoattractant concentration differences in the extracellular space that surrounds the cells. PMN are capable of detecting minute concentration differences, and this makes it possible for PMN to recognize and orient in chemotactic gradients that can be as shallow as 1 % across the length of the cell body. PMN are highly specialized to detect and distinguish numerous different chemoattractant substances that are produced by bacteria or inflamed host cells. To do so, PMN possess a variety of chemoattractant receptors. Among the best studied receptors are formyl peptide receptors (FPR), which allow PMN to recognize formylated peptides such as N-formyl-methionyl-leucyl-phenylalanine (fMLP) that are released from bacterial cell walls. Other groups of chemoattractant receptors control PMN migration in response to inflammatory mediators such as IL-8, platelet activating factor (PAF), LTB 4 , and complement fragment 5a (C5a). Once gradient sensing is accomplished, PMN polarize within the chemotactic gradient field. The cells assume an elongated morphology along the anterior-posterior axis in alignment within the chemotactic gradient field. Cell polarization enhances the efficiency and speed of the forward movement of cells [30] .
Local excitation and global inhibition model of chemotaxis. Gradient sensing requires positive feedback loops at the leading edge, allowing for directional gradient sensing of PMN in a gradient field [31] . This involves "front"-specific responses at the region experiencing the highest concentrations of chemoattractants and "rear"-specific responses where chemotactic stimulation is lowest [32] . Mathematical models and experimental evidence indicate that cells must amplify weak signal differentials of chemoattractant gradients into sharp internal differences, most clearly demonstrated by the redistribution of intracellular proteins and lipids at the front (e.g., PI3K, PIP3, Rac, F-actin) or back (e.g., PTEN, myosin, Rho) of cells [30] . However, the mechanisms by which signal amplification occurs have been the subject of much debate and controversy [33, 34] . Most current models of chemotaxis place signaling via phosphoinositide-3 kinase (PI3K) and phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at center stage. The distribution of PIP3 in the cytosol of PMN is 3 -6 times steeper than the external chemoattractant gradient, indicating the existence of a powerful amplification mechanism that aids gradient sensing and allows PMN to respond to shallow chemotactic gradients [33] . Several mechanisms have been proposed to explain how such signal amplification might occur [35 -37] . Some models suggest two distinct feedback loops: a stimulatory, positive loop that acts over a short range at the leading edge, and an inhibitory, negative feedback loop that acts over a longer range at the rear of the cell [34] . A large body of experimental evidence supports the existence of such positive and negative feedback loops that form the basis for the "Local Excitation and Global Inhibition" (LEGI) model, the most widely accepted chemotaxis model. The LEGI model incorporates the concept of opposing positive and negative regulatory feedback mechanisms and it can explain how cells remain responsive to further stimulation while they are in the process of migration [38] . The LEGI model suggests that a balance between excitation and inhibition controls membrane binding and activity of PI3K and PTEN. The dominant mechanisms that control PI3K and PTEN activity in migrating cells, however, are not well understood. We found that ATP is released at the leading edge of PMN and that ATP and positive feedback through P2Y2 receptors are critical for proper gradient sensing and correct polarization of PMN. Released ATP is rapidly converted to adenosine, while A3 adenosine receptors are distributed to the leading edge, allowing a second stage of signal amplification that controls migration speed [39] . P2Y2 and A3 receptors can induce PIP3 and Rac activation, which is a characteristic feature associated with the leading edge of polarized cells. Thus, feedback via P2Y2 and A3 receptors may explain how signal amplification is accomplished in the LEGI model of chemotaxis. In order to adapt to changing chemoattractant concentrations as cells get closer to the chemotactic source, the chemotactic receptor system of PMN is gradually desensitized, allowing the cells to maintain their gradient sensing ability over a wide range of chemoattractant concentrations [33] . Desensitization is a hallmark of many purinergic receptors [40] , providing further support for the notion that purinergic receptors are involved in the control of PMN chemotaxis.
ATP release. ATP has been long recognized as the molecular currency that provides the energy for virtually all cellular processes. Intracellular concentrations of ATP are very high, ranging from 3 -10 mM. By contrast, extracellular ATP concentrations are considerably lower. Physiological ATP concentrations in plasma are lower than 1 mM under normal conditions. Higher extracellular ATP concentrations are found under pathophysiological conditions, such as hypoxia and ischemia, that lead to cell damage, loss of cell viability, and cytolysis that results in spillage of cellular contents, including ATP, into the extracellular surroundings [41, 42] . ATP is also released by bacteria, which may help guide PMN and other inflammatory cells to sites of infection. In recent years it has become clear that, under normal physiological conditions, intact cells also can release ATP in a deliberate and controlled fashion [43 -47] . Increasing evidence suggests that released cellular ATP and the phosphohydrolytic products generated from ATP regulate cell functions via autocrine and paracrine feedback mechanisms [48 -52] . Yet, the mechanisms by which mammalian cells release ATP under these conditions are still unclear. There are two major theories as to how ATP release is accomplished. The best documented mechanism involves exocytosis of secretory granules that contain ATP. This process is observed in neurons, pancreatic cells, mast cells, and aggregating platelets [53 -58] . The second most widely accepted, yet less well understood, mechanism involves ATP release through specialA C H T U N G T R E N N U N G ized channels. Such channel-mediated release mechanisms have been proposed to facilitate ATP discharge from red blood cells, epithelial cells, smooth muscle cells, and cardiac muscle cells in response to mechanical and osmotic stimulation. Direct mechanical perturbations of the cell membrane or membrane deformation resulting from osmotic cell swelling or cell shrinkage cause the opening of mechano-sensitive channels that permit ATP to be released into the extracellular environment [48, 49, 56, 59 -62] . Work from this laboratory has shown that mechanical stimulation and osmotic stress, induced by the exposure of cells to hypertonic saline, cause rapid release of ATP from human lymphocytes and PMN [63, 64] . The released ATP and its hydrolytic product, adenosine, regulate the functional responses of these cells to osmotic stress via purinergic receptors that are expressed on the cell surface of PMN and lymphocytes [64 -66] . These findings are of clinical interest and have encouraged the increasingly wide-spread use of hypertonic resuscitation fluids to modulate the inflammatory response in trauma patients [67 -70] . During PMN chemotaxis, highly dynamic cell membrane deformation occurs predominantly at the leading edge of migrating cells. The mechanical stress exerted on the cell membrane at the leading edge is likely to cause ATP release through mechano-sensitive channels. This raises the questions whether ATP release at the leading edge may be involved in the control of chemotaxis. In support of this concept we found that chemotactic stimulation of PMN causes rapid ATP release at the leading edge and that extracellular ATP concentrations close to the cell surface appear to correlate with the extent of pseudopod activity at different membrane regions of stimulated PMN [39] . However, it is still unclear how ATP release occurs under these circumstances. The involvement of connexin hemichannels, specifically connexin 43, has been proposed [71] . It is possible that several other ATP release mechanisms also may be involved, as is suggested by preliminary results with a recently developed microscope method that allows us to visualize ATP release from living cells [72] . Maxi-anion channel activity has been identified in several cell types including cells of the immune system [52, 73 -76] . This channel type has been shown to facilitate ATP release from the macula densa, allowing osmotic sensing in the kidney [77, 78] . The molecular nature of a maxi-anion channels was first discovered a few years ago, when tweety, a gene located in Drosophila flightless, was found to resemble mammalian maxi-anion channels. Subsequently, three human maxi-anion channels (tweety homolog hTTYH1 -3) were identified by Suzuki et al. [79, 80] . Two isoforms, hTTYH1 and hTTYH3, are activated by mechanical stress and these proteins are expressed in a number of human tissues, including in peripheral blood leukocytes [79] . Thus, it is possible that hTTYH could be involved in ATP release from PMN. Finally, degranulation, which plays such an integral role in PMN physiology, is another likely mechanism that may facilitate ATP release from PMN. Cytoplasmic granules have been observed to concentrate at the leading edge of migrating cells, where these granules appear to contact the cell membrane and release their contents [81, 82] . It is possible that these PMN granules may contain ATP, as is the case in other cell types. In platelets, for example, dense granules store ADP and ATP, which play central roles in amplification of platelet aggregation and modulation of the functions of vascular endothelial cells and leukocytes [83] .
Purinergic receptors
Since the discovery by Geoffrey Burnstock and his coworkers that intact cells can release ATP, a large number of mammalian purinergic receptors have been identified and characterized [43] . Family members of these receptors are expressed in cell type-specific distribution patterns on virtually all mammalian cells, including PMN. Purinergic receptors, also termed P2 or nucleotide receptors, are divided into two major subfamilies: the GPCR-type P2Y receptors, of which eight unique isoforms have been cloned and characterized (P2Y1, 2, 4, 6, 11, 12, 13, and 14); and the P2X receptors, which are ligand-gated ion channels with seven members (P2X1 -7). The P2Y receptor subtypes trigger different signaling events, depending on the G proteins with which each is associated [43] . PMN have been reported to express the P2Y1, 2, 4, 6, 11, and 14 and P2X1, 4, 5, and 7 receptor subtypes [84, 85] . Real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis has indicated that P2Y2 seems to be the most abundantly expressed P2 receptor subtype in human PMN and HL60 cells, a PMN-like cell line that is often used to study chemotaxis [39] . P2Y2 receptors are G i coupled and can activate PIP3 and Rac [86, 87] , molecules that are tightly associated with "front"-specific cytoskeletal responses during cell polarization and chemotaxis [34] . The hydrolytic product of ATP, adenosine, is an important endogenous regulator of neutrophil functions that can modulate neutrophil activity by interacting with specific adenosine receptors on the cell surface of PMN. These adenosine receptors, also termed P1 receptors, are GPCRs and they are comprised of four unique subtypes (A1, A2a, A2b, and A3) [43] . All four P1 receptor subtypes have been reported in PMN [85] . However, recent real-time RT-PCR analysis suggests that human PMN and HL60 cells express predominantly A2a and A3 receptors [39] . These two adenosine receptor subtypes have opposing effects on the activation and functional responses of PMN. Both P1 receptor subtypes may thus cooperate to fine-tune responses of PMN to extracellular adenosine. A2a receptors are linked to G s and the cyclic AMP/protein kinase A (cAMP/ PKA) pathway, which is well known to suppress PMN responses. A3 receptors, on the other hand, stimulate PI3K pathways that up-regulate PMN responses and link to key signaling events that are associated with PMN chemotaxis [88, 89] . We observed that in resting cells, A3 receptors appear to be located primarily in intracellular compartments where they seem to associate with granules. Upon cell stimulation with chemoattractant, A3 receptors are rapidly mobilized to the cell surface of PMN [39] . Interestingly, cell polarization leads to the accumulation of A3 receptors at the leading edge, suggesting that A3 receptors are involved in regulating chemotaxis at the front of cells (Fig. 2) . In contrast, A2a receptors are uniformly distributed across the cell surface and cell polarization does not seem to change this distribution pattern. This suggests that the inhibitory A2a receptors may function to globally suppress pseudopod formation across the entire cell surface of PMN, except at the leading edge, where A3 receptors counteract the suppressive action of A2a receptors. Thus, it is possible that A2a receptors may play a role in amplifying gradient signals by suppressing chemotactic receptor signaling at membrane regions furthest away from the leading edge. This possibility is supported by the large difference in ligand affinities of the A2a and A3 receptors. A2a receptors are several orders of magnitude more sensitive to adenosine than are A3 receptors [43] . Thus, differences in external adenosine concentrations in the environment that surrounds migrating PMN may further contribute to the regulation of chemotaxis by promoting responses via A3 receptors at the leading edge, while suppressing responses via A2a receptors at other cell membrane regions.
Ecto-nucleotidases and adenosine formation. The importance of adenosine in controlling PMN chemotaxis indicates that the mechanisms that convert ATP to adenosine are equally important in regulating PMN responses. Virtually all cell types, including PMN, express on their cell surface ecto-nucleotidases [90 -92] . The large group of ecto-nucleotidases include the ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase) family, the ecto-nucleotide pyrophospha-2532 W. G. Junger ATP and adenosine regulate PMN chemotaxis tase/phosphodiesterase (E-NPP) family, the alkaline phosphatases (ALP), and ecto-5-nucleotidase (CD73) [54, 93 -98] . E-NTPDases are comprised of seven different isoforms and all are efficient enzymes with high turnover rates (NTPDase1 -6, 8; also referred to as ENTPD, ATPDase, or CD39) that hydrolyze ATP or ADP to AMP. Enzymes of the E-NPP family, which can hydrolyze ATP to AMP and PiPi pyrophosphate, consist of three members (NPP1 -3). A splice variant of NPP2, autotaxin, is soluble and converts AMP to adenosine. Alkaline phosphatases (ALP), which consist of four family members, and ecto-5-nucleotidase (CD73) catalyze the conversion of nucleotides to adenosine [97] . PMN have been shown to express E-NTPDases and CD73 [85] . PMN effectively hydrolyze extracellular ATP to AMP and adenosine [39, 71] , suggesting that PMN possess an efficient repertoire of ecto-nucleotidases. Although NTPDases likely play a role in this process [71, 99, 100] , little is known about which ectonucleotidase members are expressed in PMN. Some time ago it was shown that ecto-enzymes are present in organelles and on the cell surface of PMN. Interestingly, the enzymatic activities of these proteins and their subcellular distributions were found to change with cell stimulation [101 -104] , suggesting that these enzymes play a role in cell activation. Of the four ALP isoforms, PMN express the liver/ bone/kidney-type (non-tissue specific) alkaline phosphatase [105] . Interestingly, ALP activity in PMN of patients with various diseases is significantly different from that of healthy controls [106] . In addition, a potential involvement of ALP in the reguA C H T U N G T R E N N U N G lation of PMN chemotaxis in vivo is supported by clinical evidence, which shows that diminished ALP activity may go hand-in-hand with a loss of PMN chemotaxis and an increased incidence of infectious complications [107 -109] . ALP is present in the membranes of secretory vesicles that readily translocate from the cytoplasm to the cell membrane [108] . Thus, the activation of PMN may increase the presence of ALP on the cell surface, potentially allowing ALP to modulate PMN chemotaxis by generating extracellular adenosine.
Purinergic control of chemotaxis
A number of reports have shown that addition of exogenous ATP or adenosine can either inhibit or promote neutrophil chemotaxis [110 -115] . These contradictory reports can be explained in light of our findings that purinergic signaling systems that are susceptible to ATP and adenosine control several key steps of chemotaxis. We found that the chemoattractant fMLP stimulates the release of ATP from PMN and that this response is greatest at cell membrane areas that are closest to the source of chemoattractant [39] . This suggests that ATP and positive feedback via P2Y2 receptors may be required for gradient sensing. This concept is supported by our findings that scavengers of extracellular ATP, inhibitors of P2 receptors, and the absence of P2Y2 receptors in PMN from P2Y2 knockout (KO) mice render cells unable to orient in a chemotactic gradient field (Fig. 3) . ATP and feedback via P2Y2 receptors near sites where ATP is released may constitute a mechanism that significantly amplifies weak chemotactic signal. Chemoattractant receptors and P2Y2 receptors remain uniformly distributed across the cell surface and this does not change after cell polarization [28, 29, 39] . This is critical for PMN, because it allows them to maintain their keen gradient sensing ability while they migrate upstream a chemotactic gradient field.
Once a cell has determined the orientation of the chemotactic gradient field, it rapidly polarizes, assumes an elongated shape, and aligns itself within the chemotactic gradient field. This process involves the accumulation of A3 receptors and likely of ectonucleotidases at the leading edge, which allows the conversion of ATP to adenosine. The proximity of adenosine and A3 adenosine receptors at the leading edge allows for a second round of signal amplification. For chemotaxis, this second amplification step is equal in importance to the initial amplification that facilitates gradient sensing. We found that disruption of the latter feedback mechanism with scavengers of extracellular adenosine or A3 adenosine receptor antagonists, or due to the lack of A3 adenosine receptors in PMN from A3 receptor knockout mice, significantly Cells were stably transfected to express EGFP-A3 adenosine receptor fusion protein, differentiated to acquire PMN-like characteristics, and subjected to a chemotactic gradient field that was generated by releasing fMLP from a micropipette (top).
Cell. Mol. Life Sci. Vol. 65, 2008 Review Article impairs chemotaxis. Interference with adenosine signaling significantly reduced migration speed; however, the cells did not lose their ability to detect and correctly orient in the chemotactic gradient field. The role of A2a receptors in the purinergic control of chemotaxis is less well established. A2a receptors seem to remain uniformly distributed across the cell surface during chemotaxis [39] . This, together with the high affinity of A2a receptors for adenosine and their known suppressive effects on PMN responses, suggests that A2a receptors may participate in controlling PMN chemotaxis. It is likely that A2a receptors finetune chemotactic responses by facilitating membrane retraction at the receding edge or by inhibiting chemotactic receptor activation at membrane regions away from the leading edge. Thus, P2Y2 and A3 receptors at the leading edge of PMN seem to facilitate gradient sensing and cell migration, respectively, by activating hallmark signaling molecules associated with front-specific events at the leading edge of polarized cells, while A2a receptors may suppress chemotactic receptor signaling at the trailing edge and thus facilitate membrane retraction at the posterior of cells, where adenosine concentrations are low but sufficient to activate high-affinity A2a adenosine receptors.
Neutrophil abnormalities
The importance of PMN in protecting the host from infections is exemplified by a number of neutrophil abnormalities that severely impair host defense, resulting in recurring infections. PMN dysfunction of chemotaxis may be caused indirectly by the absence of mediators needed to generate chemotactic gradients, for example complement components that form C5a, or by abnormalities of cytoplasmic and granule movement that directly affect chemotactic responses [116 -118] .
Patients with such disorders are susceptible to infections with a wide spectrum of micro-organisms, including fungi, gram-positive and gram-negative bacteria. Staphylococcus aureus infections of the skin, gingival mucosa, and regional lymph nodes are the most frequent bacterial symptoms. Depressed neutrophil chemotaxis has been observed in a wide variety of clinical conditions, including patients suffering from hyperimmunoglobulin E syndrome, Jobs syndrome, chronic granulomatous disease, leukocyte adhesion deficiency, and Chediak-Higashi syndrome. At least some of these inherited diseases seem to be associated with defective actin polymerization or granule morphogenesis, with mutation of Rac2, rendering this important signaling molecule unable to bind GTP [119, 120] , or with molecular defects that involve CD11 integrins [121, 122] . In most of these diseases, PMN chemotaxis is slowed but PMN remain able to ultimately reach infected sites, suggesting that PMN can compensate, at least in part, for lost functions. Interestingly, knockout mice deficient in either P2Y2 or A3 receptors have defects in the ability to recruit PMN to the peritoneum in response to a septic challenge. However, as in some inherited diseases characterized by defective PMN chemotaxis, P2Y2 and A3 KO mice seemed to compensate for that defect by increasing the numbers of circulating PMN and by increasing the numbers of resident PMN that are dispatched to the peritoneal cavity in healthy animals [39] . Perhaps this is the reason why P2Y2 and A3 KO mice do not appear to suffer from recurrent infectious complications, despite severely impaired PMN chemotaxis. Apoptosis PMN apoptosis and the phagocytosis of dying PMN by macrophages are responsible for the clearance of neutrophils from inflamed tissues, which is required for the resolution of acute inflammatory responses [123] . This process is delayed by ATP, which inhibits PMN apoptosis in the presence of growth factors [124] . Adenosine has been shown to either promote or inhibit apoptosis through actions on A3 or A2a adenosine receptors, respectively [125 -127] . Interestingly, adenosine is found in synovial fluid samples from patients with rheumatoid arthritis, and the concentrations of adenosine in these samples appear to correlate with inhibitory actions of synovial fluid samples on apoptosis of PMN in vitro [128] . However, it is difficult to predict how adenosine influences PMN apoptosis in vivo where factors such as a varying fraction of A3 versus A2a receptors expressed on the cell surface of PMN and different adenosine concentrations in microenvironments near the PMN surface may determine the cells functional responses. Moreover, effector cells such as gdT cells can recognize and kill PMN by direct cellto-cell interactions, and thus contribute to the clearance of PMN from inflamed host tissues [129] . It is likely that extracellular adenosine and ATP control PMN apoptosis, not only directly but also indirectly by modulating the functions of gdT cells and other cells that are responsible for the clearance of PMN from inflamed sites.
Control of inflammation by ATP and adenosine
Pathological conditions that result in severe cellular distress and cell damage cause ATP release into the extracellular space. For example, hypoxia and tissue injury increase the concentrations of ATP and inflammatory mediators in the circulation in response to hemorrhagic or septic shock. Released ATP is converted to adenosine, which may help prevent excessive phagocyte activation [130] . A large body of evidence suggests that ATP and adenosine could benefit patients with acute inflammatory episodes by modulating functions of immune cells that are involved in the inflammatory response [131] . Indeed, several studies have shown protective effects of infusion of adenoA C H T U N G T R E N N U N G sine or ATP-MgCl 2 , which is rapidly converted to adenosine, in animal models of hemorrhagic or septic shock [131 -133] . In addition, ATP and adenosine have been shown to protect lung tissue from ischemia/reperfusion injury [130, 134 -137] . Therefore, adenosine is considered an innate protective agent that prevents tissue damage in response to acute or chronic inflammation. Because of the destructive role of PMN in these settings, it is clear that the protective actions of adenosine are, at least in part, due to the suppressive effects of adenosine on PMN. Unfortunately, the clinical use of ATP-MgCl 2 and adenosine treatment is hampered by serious side effects that target particularly the cardiovascular system. In attempts to overcome these sequelae, a number of approaches were devised. These approaches induce localized increases in extracellular adenosine concentrations close to the surface of PMN, for example, using inhibitors that target adenosine kinase, adenosine deaminase, or nucleotide transporters [131] . These therapeutic approaches maintain moderately elevated yet consistent levels of adenosine by preventing its phosphorylation, hydrolysis, or cellular re-uptake, respectively. Inhibitors that target these three major processes have also been shown to suppress TNF production in human PMN and to prevent leukocyte adhesion after hemorrhagic shock, endotoxeA C H T U N G T R E N N U N G mia, sepsis, colitis, liver ischemia, and reperfusion injury [137 -142] . We demonstrated that hypertonic resuscitation fluids can induce the release of ATP from leukocytes, which also results in increased localized concentrations of extracellular adenosine close to the cell surface of PMN. This leads to the suppression of PMN via A2a adenosine receptors [64, 65, 143] . Hypertonic resuscitation fluids were shown to reduce acute inflammatory responses and PMN-induced host tissue injury in a number of animal models of shock [67] . ATP and adenosine regulate many PMN responses including chemotaxis. Therefore, it can be expected that adenosine receptors will be increasingly targeted in future therapeutic approaches to modulate chemotaxis, so as to either reduce PMN recruitment to inflamed tissues or to encourage PMN recruitment to sites of infection.
Adenosine receptors as pharmacological targets to control chemotaxis
All four adenosine receptors are targets of caffeine and related alkaloid drugs widely consumed in the form of tea or coffee. These drugs affect a multitude of physiological processes owing to the abundant expression of the different adenosine receptors in most tissues. A growing body of evidence suggests that pharmacological agents derived from caffeine can be used to target specific adenosine receptor subtypes in various tissues, which would make it possible to treat a number of different conditions including inflammatory diseases. Over the years, highly selective agonists and antagonists of the four adenosine receptor Cell. Mol. Life Sci. Vol. 65, 2008 Review Article subtypes have been developed [144, 145] . Table 1 summarizes some of these agents.
In the context of this review, drugs that affect A2a and A3 adenosine receptors are of particular interest because the receptors are highly expressed in PMN and appear to play key roles in controlling PMN chemotaxis. We found that MRS 1191, an A3 receptor antagonist, impairs chemotaxis of human PMN in vitro by inhibiting the rate of migration [39] , while the A2a receptor agonist CGS 21680 appears to reduce chemotaxis by affecting retraction of the receding edge (unpublished data). In vivo studies with A3 receptor deficient mice support the concept that inhibition or elimination of A3 adenosine receptors may prove useful to reduce PMN chemotaxis in response to inflammatory challenges [39] . Agonists of A3 receptors enhance PMN chemotaxis in vitro [39] . Interestingly, leukocytes of rheumatoid arthritis patients have been found to over-express A3 adenosine receptors, suggesting that increased A3 receptor expression could be related to the accumulation of PMN in inflamed joints [146] . Taken together, these findings imply that A3 receptors are potential pharmacological targets for novel therapies aimed at stemming the inflammatory response, for example, in rheumatoid arthritis [147, 148] . Ample evidence suggests that A2a receptor agonists, which inhibit PMN functions, including chemotaxis, by increasing intracellular cAMP levels, may also prove useful to prevent PMN accumulation and tissue damage in a number of inflammatory complications, particularly chronic airway inflammation and related respiratory disorders [149 -151] .
The potential therapeutic value of drugs that target A3 receptors may not be limited to inhibiting PMN chemotaxis, as A3 adenosine receptors may also play a role in the migration of other cell types, possibly including cancer cells. Thus, pharmacological targeting of A3 receptors could find use in treating certain types of cancer, a hypothesis that is strengthened by preclinical findings that chronic use of A3 receptor agonists may be useful for the treatment of breast and colon cancers, and by the observation that colorectal cancer is associated with elevated A3 receptor expression [152 -154] .
The underlying mechanisms of action are not fully understood, but it is possible that chronic use of A3 receptor agonists may either cause receptor desensitization, receptor internalization, or simply interfere with chemotaxis processes by obscuring endogenous adenosine gradients that drive directed cell migration. Although the results of preclinical studies suggest that drugs that target adenosine receptors may be efficacious to treat a variety of diseases such as cancer, arthritis, and a host of other inflammatory diseases, none of these drugs has yet received regulatory approval. However, this may change as our understanding of the complex mechanisms that govern the expression and activation of adenosine receptors in different host tissues improves due to the relentless efforts of many experts in the respective research fields. 
